A Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran

INTRODUCTION: In the pivotal RE-LY trial, dabigatran etexilate (DE) at the dose of 150-mg twice daily (BID), significantly reduced total stroke and ischemic stroke compared with warfarin in patients with non-valvular atrial fibrillation (NVAF), while the 110-mg BID dose had efficacy equivalent to wa...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Dea, Daniel, Whetteckey, Jacqueline, Ting, Naitee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125113/
https://www.ncbi.nlm.nih.gov/pubmed/27709460
http://dx.doi.org/10.1007/s40119-016-0071-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125113/
https://www.ncbi.nlm.nih.gov/pubmed/27709460
http://dx.doi.org/10.1007/s40119-016-0071-5

Ejemplares similares